Initiate rolling submission of the Biologics License Application for the COVID-19 vaccine in the U.S

Delivered after the deadline (1 days after the deadline)

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 6 May 2021
Due: 31 May 2021
Delivered: 1 Jun 2021

Deadline
Met
Late
Not met
Today

What the company said

“The Company plans to initiate rolling submission for a Biologics License Application (BLA) for the vaccine in the U.S. this month.”

SourceModerna Form 8-K press release, 2021-05-06
FilingSEC filing index
Deadline as statedthis month
Deadline used31 May 2021, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2021-MRNA-006167
Cite as https://keptindex.org/c/KI-C-2021-MRNA-006167/ — this address never changes.

What we found

Evidence strength A What the grades mean

Moderna's August 2021 filings state it initiated the rolling BLA submission on June 1, 2021, one day after the May 31 deadline.

A
Moderna 8-K filed 2021-08-05 Regulatory filing · published 5 Aug 2021 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint cb41d14e96b0
“On June 1, 2021, the Company initiated the rolling submission process for a Biologics License Application (BLA) for the vaccine in the U.S.” ✓ confirmed on the page
A
Moderna 10-Q filed 2021-08-05 Regulatory filing · published 5 Aug 2021 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 45e20d6e1336
“On June 1, 2021, we initiated the rolling submission process with the U.S. FDA for a Biologics License Application for our COVID-19 vaccine” ✓ confirmed on the page

Market reaction: the shares moved +14.9% against the S&P 500 over the three sessions around the disclosure (4 Aug 2021 to 9 Aug 2021). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

1 versions

Version 1 · original · stated 6 May 2021

Deadline 31 May 2021 (“this month”) · wording expected
Version 2 · stated 5 Aug 2021

Deadline 31 Aug 2021 (“in August”) · wording expected

“expects to complete its submission in August”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory other
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Rolling BLA submission for COVID-19 vaccine (mRNA-1273)
Where: U.S.
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.